Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
group_2_presentation_1_-_glioblastoma [2017/10/05 13:12] alisb |
group_2_presentation_1_-_glioblastoma [2018/01/25 15:19] (current) |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ===== Etiology ===== | + | Link to ppt: https://docs.google.com/a/mcmaster.ca/presentation/d/1aPDGB9N-jfVw91J4yq4N44fnEg5pGluNftePloslFag/edit?usp=sharing |
| + | ====== Introduction ====== | ||
| - | Glioblastomas (GBM) are the most common aggressive malignant tumors found in adults (Davis 2016). The onset tends to occur in glial tissue of the central nervous system, with most tumors found in the brain. Primary glioblastomas originate de novo, meaning they do not arise from previously present tumors or cancerous precursors in the central nervous system. In contrast, secondary tumors arise from previously existing low grade tumors that develop into GBM (Davis, 2016). Moreover, Gliomas could be astrocytic, oligodendrocytic, or a mix of both. Overall, there are few potential carcinogenic risk factors that can influence the onset of glioblastoma in the central nervous system. For instance, exposure to high doses of ionizing radiation is regarded as the only confirmed risk factor. | + | Glioblastomas (GBM) are the most common aggressive malignant tumors found in adults (Davis 2016). The onset tends to occur in glial tissue of the central nervous system, with most tumors found in the brain. Primary glioblastomas originate de novo, meaning they do not arise from previously present tumors or cancerous precursors in the central nervous system. In contrast, secondary tumors arise from previously existing low grade tumors that develop into GBM (Davis, 2016). Most cases of GBM tend to be sporadic and result from a complex mutation rather than a genetic predisposition. However, the cancer can result from the metastasis of peripheral cancer cells located commonly in the breast and lungs, effectively evading immunological responses upon penetrating the blood-brain barrier (Davis, 2016) Moreover, Gliomas could be astrocytic, oligodendrocytic, or a mix of both. Overall, there are few potential carcinogenic risk factors that can influence the onset of glioblastoma in the central nervous system. For instance, exposure to high doses of ionizing radiation is regarded as the only confirmed risk factor (Davis, 2016). |
| ===== Epidemiology ===== | ===== Epidemiology ===== | ||
| - | The incidence rate of gliomas depends on its histologic type, age at diagnosis, gender, race, and country. However, it is hard to compare and accurately define the incidence rate due to its variation in the different types and its inconsistency of definition resulting in different data collections. | + | The data for the incidence rate of gliomas vary according to the histologic type of cancer, age at diagnosis, the gender and race of the patients, and prevalence per country. According to a epidemiologic review conducted by Thakkar et al. (2014), the age-adjusted incidence rates range from 4.67 to 5.73 per 100 000 persons being diagnosed with Glioblastoma per year. Moreover, the study found that anaplastic astrocytoma and glioblastoma increase in incidence with age, peaking in the 75–84 age group. Oligodendrogliomas and oligoastrocytomas are most common in the 35–44 age group. Figure 1 provides data on the prevalence of GBM according to age and gender, suggesting that the cancer is more common among men and adults within the 50-70 ranged age group (Thakkar et al., 2014). |
| - | According to a review, the age-adjusted incidence rates range from 4.67 to 5.73 per 100 000 persons (Thakkar et al. 2014). Anaplastic astrocytoma and glioblastoma increase in incidence with age, peaking in the 75–84 age group. Oligodendrogliomas and oligoastrocytomas are most common in the 35–44 age group. Figure 1 provides data on the prevalence of GBM according to age and gender, suggesting that the cancer is more common among men and adults within the 50-70 ranged age group. | + | Prognostic factors that influence patient survivability and subsequently, the incidence rate, include the extent of tumor resection, the age of diagnosis, and the results of the patient's Karnofsky performance, which classifies patients based on their degree of functional impairment (Walid, 2008). Glioblastomas have a low survival rate of approximately 0.05% to 4.7% 5 years past diagnosis (Thakkar et al., 2014). Oligodendrogial types have a relatively higher survival rate of survivability in comparison to the astrocytomas. Overall, early surgical resection exhibits a higer chance of survival compared to postponed treatment. |
| - | + | ||
| - | Prognostic factors include the extent of tumor resection, the age of diagnosis, and the Karnofsky performance. Glioblastomas have a low survival rate of around 0.05% to 4.7% 5 years past diagnosis. Oligodendrogial types have a relatively higher survival rate in comparison with the astrocytic type. Overall, early surgical resection had a higer chance of surviving compared to waiting and biopsy. | + | |
| Line 33: | Line 32: | ||
| {{ :damage_brain.gif |}} | {{ :damage_brain.gif |}} | ||
| - | Figure _: Effect glioblastoma has on each area of the brain. | + | **Figure 2**: Effect glioblastoma has on each area of the brain. |
| ====== Diagnosis ====== | ====== Diagnosis ====== | ||
| Line 46: | Line 45: | ||
| Initially, a computed tomography (CT scan) which looks at the soft tissue of the brain and is accurate in the detection of larger scale tumors of varying stages. However, CT scanning may not possess the resolution to detect small multifocal tumors that may present or transform into glioblastoma multiform. In addition, cerebrospinal fluid (CSF) spread may be difficult to detect with CT scanning (Davis 2016). | Initially, a computed tomography (CT scan) which looks at the soft tissue of the brain and is accurate in the detection of larger scale tumors of varying stages. However, CT scanning may not possess the resolution to detect small multifocal tumors that may present or transform into glioblastoma multiform. In addition, cerebrospinal fluid (CSF) spread may be difficult to detect with CT scanning (Davis 2016). | ||
| - | Moreover, an MRI scan applies a gadolinium contrast dye to the glioblastoma cells to identify the presence of an irregularly shaped tumor exhibiting a dense cellular outer ring and an inner ring of necrosis, a key feature indicative of GBM (Bosnyak et al. 2016). Moreover, brain scans may also reveal the presence of vasogenic edema peripheral to the primary tumor location, and as a result, potential hemorrhaging and displacement of the brain’s ventricles containing cerebrospinal fluid (Davis 2016). Figure 2 depicts an MRI scan and an MRI/PET fusion scan to illustrate a high grade glioma with central necrosis, high glucose metabolism and the presence of peripheral edema. | + | Moreover, an MRI scan applies a gadolinium contrast dye to the glioblastoma cells to identify the presence of an irregularly shaped tumor exhibiting a dense cellular outer ring and an inner ring of necrosis, a key feature indicative of GBM (Bosnyak et al. 2016). Moreover, brain scans may also reveal the presence of vasogenic edema peripheral to the primary tumor location, and as a result, potential hemorrhaging and displacement of the brain’s ventricles containing cerebrospinal fluid (Davis 2016). Figure 3 depicts an MRI scan and an MRI/PET fusion scan to illustrate a high grade glioma with central necrosis, high glucose metabolism and the presence of peripheral edema. |
| Furthermore, in approximately 13% of cases, GBM is presented as more than 2 lesions (multifocal) with a distant secondary lesion that is discontinuous with the primary lesion (Bosnyak et al. 2016). | Furthermore, in approximately 13% of cases, GBM is presented as more than 2 lesions (multifocal) with a distant secondary lesion that is discontinuous with the primary lesion (Bosnyak et al. 2016). | ||
| Line 52: | Line 51: | ||
| {{:glioblastoma_mri.jpg?500 |}} | {{:glioblastoma_mri.jpg?500 |}} | ||
| - | **Figure 2** : This figure depicts an MRI scan and an MRI/PET fusion scan of a patient brain exhibiting a left parieto-occipital glioblastoma. | + | **Figure 3** : This figure depicts an MRI scan and an MRI/PET fusion scan of a patient brain exhibiting a left parieto-occipital glioblastoma. |
| ===== Tumor Classification ===== | ===== Tumor Classification ===== | ||
| Line 65: | Line 64: | ||
| ====== Brain Physiology ====== | ====== Brain Physiology ====== | ||
| - | The brain can be divided into two major components; white matter and grey matter. The grey matter consists of the cell bodies, axons and dendrites, it is where all the neuronal connections occur. The white matter consists of the glial cells and the myelinated axons that connect cell bodies to one another (Henson, 1999). Glioblastomas tend to occur in two subsets of the glial cells—astrocytes and oligodendrocytes. Astrocytes maintain the appropriate environment for neuronal signalling and are star-shaped cells that give the brain its shape. Astrocytes are the most common cell type to become tumours. Oligodendrocytes are responsible for forming myelin sheaths around axons. Tumours of oligodendrocytes are less common than astrocytomas. Many tumours contain a mixture of astrocytoma and oligodendroglioma cells. Tumours of other cell types in the brain are less common. For instance, tumours of neurons are very rare in adults (Henson, 1999). | + | The brain can be divided into two major components; white matter and grey matter (Figure 4). The grey matter consists of the cell bodies, axons and dendrites, it is where all the neuronal connections occur. The white matter consists of the glial cells and the myelinated axons that connect cell bodies to one another (Henson, 1999). Glioblastomas tend to occur in two subsets of the glial cells—astrocytes and oligodendrocytes. Astrocytes maintain the appropriate environment for neuronal signalling and are star-shaped cells that give the brain its shape. Astrocytes are the most common cell type to become tumours. Oligodendrocytes are responsible for forming myelin sheaths around axons. Tumours of oligodendrocytes are less common than astrocytomas. Many tumours contain a mixture of astrocytoma and oligodendroglioma cells. Tumours of other cell types in the brain are less common. For instance, tumours of neurons are very rare in adults (Henson, 1999). |
| {{ :18117.jpg?500 |}} | {{ :18117.jpg?500 |}} | ||
| - | **Figure 3**: Glioblastomas occur in glial cells, which are located in the white matter of the brain. | + | **Figure 4**: Glioblastomas occur in glial cells, which are located in the white matter of the brain. |
| ===== Pathophysiology of Glioblastomas ===== | ===== Pathophysiology of Glioblastomas ===== | ||
| === Overview of Tumorigenesis === | === Overview of Tumorigenesis === | ||
| - | Six general intracellular events which lead to the development of glioblastoma. These steps do not occur in isolation, but the accumulation of these will lead to tumorigenesis. The first event is loss of cell cycle control. Normal cells have many checkpoints during the cell cycle to keep proliferation in control. However, in glioblastoma, genetic defects occur leading to uncontrolled regulation of the cell cycle causing proliferation. The second event that occurs is overexpression of growth factors and their receptors. This overexpression provides growth advantage to tumor cells, increasing their survivability. A third event that occurs in glioblastoma is angiogenesis. Glioblastoma is a vascular tumor, and thus needs angiogenesis to support itself. Another critical feature in glioblastoma is the mutation of stem cells into tumor cells*. Moreover, abnormal apoptosis is a significant feature in tumorigenesis. Genetic mutations, such as p53, disrupt normal apoptotic responses, and allow further progression of the cell cycle. Lastly, genetic instability allows for the accumulation of mutations. Some of these mutations will be advantageous since it will be a more malignant clone (Nakada et al. 2011). | + | Six general intracellular events which lead to the development of glioblastoma. These steps do not occur in isolation, but the accumulation of these will lead to tumorigenesis. The first event is loss of cell cycle control. Normal cells have many checkpoints during the cell cycle to keep proliferation in control. However, in glioblastoma, genetic defects occur leading to uncontrolled regulation of the cell cycle causing proliferation. The second event that occurs is overexpression of growth factors and their receptors. This overexpression provides a growth advantage to tumor cells, increasing their survivability. A third event that occurs in glioblastoma is angiogenesis. Glioblastoma is a vascular tumor, and thus needs angiogenesis to support itself. Another critical feature in glioblastoma is the mutation of stem cells into tumor cells. Moreover, abnormal apoptosis is a significant feature in tumorigenesis. Genetic mutations, such as p53, disrupt normal apoptotic responses, and allow further progression of the cell cycle. Lastly, genetic instability allows for the accumulation of mutations. Some of these mutations will be advantageous since it will be a more malignant clone (Nakada et al. 2011).These steps are outlined in Figure 5. |
| {{ :6image.png |}} | {{ :6image.png |}} | ||
| - | Figure_: The six intracellular events that allow normal cells to be transformed to cancerous cells, through a process called tumorigenesis. | + | **Figure 5**: The six intracellular events that allow normal cells to be transformed to cancerous cells, through a process called tumorigenesis. |
| ===Loss of Cell Cycle Control=== | ===Loss of Cell Cycle Control=== | ||
| - | In normal conditions, the process of cellular division is highly regulated with numerous checkpoints that either allow the progression of the cell cycle or induce apoptosis in the presence of mutations. Cancerous cells evade these restrictions resulting in uncontrolled cellular proliferation. One mechanism to accomplish this is mutating the Rb/E2F pathway. Rb/E2F mediates the transition of G1 phase to S phase (Alifieris, 2015). Transcription factor E2F is responsible for upregulating genes to promote DNA synthesis. Ordinarily Retinoblastoma protein (Rb) binds and inhibits the activation of E2F (Nevins, 2001). To progress to S phase, Cyclin D-cyclin dependent kinase 2 (CDK-2) and Cyclin E-CDK4 phosphorylate the Rb protein rendering it inactive. The cell is then able to advance to S phase via E2F (Nevins, 2001). Tumour analysis showed mutations in the Rb gene allowed the cell to enter a cancerous state. After this conversion, cancerous cells are also able to upregulate genes coding for Cylin-CDK4 to promote the phosphorylation of Rb and therefore the activation of E2F (Nevins, 2001). | + | In normal conditions (Figure 6), the process of cellular division is highly regulated with numerous checkpoints that either allow the progression of the cell cycle or induce apoptosis in the presence of mutations. Cancerous cells evade these restrictions resulting in uncontrolled cellular proliferation. One mechanism to accomplish this is mutating the Rb/E2F pathway. Rb/E2F mediates the transition of G1 phase to S phase (Alifieris, 2015). Transcription factor E2F is responsible for upregulating genes to promote DNA synthesis. Ordinarily Retinoblastoma protein (Rb) binds and inhibits the activation of E2F (Nevins, 2001). To progress to S phase, Cyclin D-cyclin dependent kinase 2 (CDK-2) and Cyclin E-CDK4 phosphorylate the Rb protein rendering it inactive. The cell is then able to advance to S phase via E2F (Nevins, 2001). Tumour analysis showed mutations in the Rb gene allowed the cell to enter a cancerous state. After this conversion, cancerous cells are also able to upregulate genes coding for Cylin-CDK4 to promote the phosphorylation of Rb and therefore the activation of E2F (Nevins, 2001). |
| Line 84: | Line 83: | ||
| - | Figure_: Cyclin E and CDK4 phosphorylate Rb rendering it inactive and allowing E2F to up regulate DNA synthesis genes. | + | **Figure 6**: Cyclin E and CDK4 phosphorylate Rb rendering it inactive and allowing E2F to up regulate DNA synthesis genes. |
| ===Stem Cells=== | ===Stem Cells=== | ||
| - | Stem cells are undifferentiated cells that are able to undergo continuous proliferation to give rise to specialized differentiated cells. During fetal growth, embryonic stem cells are known as pluripotent, meaning they can give rise to any tissue type (Ahmed, 2013). As development progresses post-partum, stem cells lose plasticity and become multipotent, meaning they can only give rise to cells of a particular tissue type (Ahmed, 2013). In many cases, cancer arises due to the uncontrollable proliferation of stem cells. In the case of GBM, glioma stem cells (GBS) have the capability of becoming tumor initiating cells (TICs) (Ahmed, 2011). The primary reason GBM has a high relapse rate is because of the heterogeneity of the GBM tumour. When GSCs divide, they give rise to another GSC with self-renewal properties and a differentiated bulk cell which contributes to the tumour size (Ahmed, 2013). Along with unregulated proliferation, GSCs also have the capability to upregulate transcription factors such as VEGF to promote angiogenesis (Alifieris, 2015). Tt has been determined that GSCs upregulate certain antigens on their cellular membrane to increase tumor-like characteristics that are not observed in regular differentiated cells. An example of this, is antigen CD133+ which shown in vitro to give rise to “tumor spheres” when cultured in optimal conditions (Ahmed, 2013). | + | Stem cells are undifferentiated cells that are able to undergo continuous proliferation to give rise to specialized differentiated cells. During fetal growth, embryonic stem cells are known as pluripotent, meaning they can give rise to any tissue type (Ahmed, 2013). As development progresses post-partum, stem cells lose plasticity and become multipotent, meaning they can only give rise to cells of a particular tissue type (Ahmed, 2013). In many cases, cancer arises due to the uncontrollable proliferation of stem cells. In the case of GBM, glioma stem cells (GBS) have the capability of becoming tumor initiating cells (TICs) (Ahmed, 2013). The primary reason GBM has a high relapse rate is because of the heterogeneity of the GBM tumour. When GSCs divide (Figure 7), they give rise to another GSC with self-renewal properties and a differentiated bulk cell which contributes to the tumour size (Ahmed, 2013). Along with unregulated proliferation, GSCs also have the capability to upregulate transcription factors such as VEGF to promote angiogenesis (Alifieris, 2015). Tt has been determined that GSCs upregulate certain antigens on their cellular membrane to increase tumor-like characteristics that are not observed in regular differentiated cells. An example of this, is antigen CD133+ which shown in vitro to give rise to “tumor spheres” when cultured in optimal conditions (Ahmed, 2013). |
| {{:gscs.png|}} | {{:gscs.png|}} | ||
| - | Figure_: GSCs give rise to a daughter GSCs with self-renewal properties as well as a differentiation bulk cell with contributes to tumour size. | + | **Figure 7**: GSCs give rise to a daughter GSCs with self-renewal properties as well as a differentiation bulk cell with contributes to tumour size. |
| ===PI3K pathway=== | ===PI3K pathway=== | ||
| - | Upregulation of many Receptor Tyrosine Kinase, such as Endothelial Growth Factor Receptor (EGFR), can be observed in a cancerous environment. EGFR activation leads to upregulation of angiogenesis, proliferation, differentiation and cell metastasis (Herbst, 2003). In GMB cell samples it has been shown that the extracellular domain of the EGFR has been deleted leading to ligand independent cell signaling (Herbst, 2003). EGFR activates by auto phosphorylating its tyrosine domain which allows cellular kinases such as Phosphoinositide 3-Kinase (PI3K) (Alifieris, 2015). PI3K then goes on to phosphorylate proteins such as PIP3 and PIP2 via its p110alpha catalytic subunit. Phosphorylation of PIP3 and PIP2 leads to the activation of Akt which then geos on to upregulate cells to promote cellular proliferation, differentiation and survival (Alifieris, 2015). In a cancerous environment, it has been observed that the p110alpha domain of PI3K has been upregulated to accelerated cellular division (Alifieris, 2015). | + | Upregulation of many Receptor Tyrosine Kinase, such as Endothelial Growth Factor Receptor (EGFR), can be observed in a cancerous environment. EGFR activation leads to upregulation of angiogenesis, proliferation, differentiation and cell metastasis (Herbst, 2003). In GMB cell samples it has been shown that the extracellular domain of the EGFR has been deleted leading to ligand independent cell signaling (Herbst, 2003). Referring to Figure 8, EGFR activates by auto phosphorylating its tyrosine domain which allows cellular kinases such as Phosphoinositide 3-Kinase (PI3K) (Alifieris, 2015). PI3K then goes on to phosphorylate proteins such as PIP3 and PIP2 via its p110alpha catalytic subunit. Phosphorylation of PIP3 and PIP2 leads to the activation of Akt which then geos on to upregulate cells to promote cellular proliferation, differentiation and survival (Alifieris, 2015). In a cancerous environment, it has been observed that the p110alpha domain of PI3K has been upregulated to accelerated cellular division (Alifieris, 2015). |
| {{:PI3K_pathway.png|}} | {{:PI3K_pathway.png|}} | ||
| - | Figure_: EFGR auto-phosphorylates to recruit PI3K. PI3K phosphorylates PIP3 and PIP2 which then go on to activate Akt to up regulate genes that promote cell survival. | + | **Figure 8**: EFGR auto-phosphorylates to recruit PI3K. PI3K phosphorylates PIP3 and PIP2 which then go on to activate Akt to up regulate genes that promote cell survival. |
| === Angiogenesis === | === Angiogenesis === | ||
| - | Angiogenesis is initiated by angiogenic factor such as VEGF and FGF, which stimulate growth of endothelial cells. These are secreted in high concentrations from endothelial cells near the tumor, in a hypoxic microenvironment. The angiogenic factors bind to cognate receptors found on endothelial cells, leading to endothelial cell proliferation and migration. Then, there is a breakdown of local extracellular matrix, via MMPs, to provide room for new blood vessels to form. Next, angiopoietins (Ang-2) are secreted from the glioma cells to allow stability and maintenance of the new vasculature. Ang will bind to Tie-2 and destabilize vessels. After this breakdown and destabilization, endothelial cells gather into a tubular lumen. Individual sprouts are connected and form a vascular loop to allow for blood flow. Pericytes are then recruited and assemble on the outside off the new vasculature to allow maturation. Once a basement membrane is formed angiogenesis is complete (Nakada et al. 2011). | + | Angiogenesis is initiated by angiogenic factor such as VEGF and FGF, which stimulate growth of endothelial cells. These are secreted in high concentrations from endothelial cells near the tumor, in a hypoxic microenvironment. The angiogenic factors bind to cognate receptors found on endothelial cells, leading to endothelial cell proliferation and migration. Then, there is a breakdown of local extracellular matrix, via MMPs, to provide room for new blood vessels to form. Next, angiopoietins (Ang-2) are secreted from the glioma cells to allow stability and maintenance of the new vasculature. Ang will bind to Tie-2 and destabilize vessels. After this breakdown and destabilization, endothelial cells gather into a tubular lumen. Individual sprouts are connected and form a vascular loop to allow for blood flow. Pericytes are then recruited and assemble on the outside of the new vasculature to allow maturation. Once a basement membrane is formed angiogenesis is complete (Nakada et al. 2011). These steps are summarized in figure 9. |
| {{ :angio13.png |}} | {{ :angio13.png |}} | ||
| - | Figure _: Steps for glioblastoma to undergo angiogenesis. Angiogenesis is a necessary process that allows glioma cells to survive and continue to proliferate. | + | **Figure 9**: Steps for glioblastoma to undergo angiogenesis. Angiogenesis is a necessary process that allows glioma cells to survive and continue to proliferate. |
| === p53 Pathway Mutation === | === p53 Pathway Mutation === | ||
| Line 111: | Line 110: | ||
| ARF is a tumor suppressor protein that is an upstream regulator of the p53 pathway. ARF can directly bind to MDM2 and inactivate the E3 ligase activity, leading to activation of the p53 pathway. However, in glioblastoma, ARF is inactivated or mutated, leading to proliferation by continuation of the cell cycle (Mao et al. 2012). | ARF is a tumor suppressor protein that is an upstream regulator of the p53 pathway. ARF can directly bind to MDM2 and inactivate the E3 ligase activity, leading to activation of the p53 pathway. However, in glioblastoma, ARF is inactivated or mutated, leading to proliferation by continuation of the cell cycle (Mao et al. 2012). | ||
| {{ :p53_pathway_to_hell.png |}} | {{ :p53_pathway_to_hell.png |}} | ||
| - | Figure_: Rb binds to inhibit E2F. When the cell is ready to move to S phase, Cyclin E-CDK4 phosphorylates Rb rendering it inactive, allowing E2F to up regulate genes responsible for DNA synthesis. | + | **Figure 10**: Rb binds to inhibit E2F. When the cell is ready to move to S phase, Cyclin E-CDK4 phosphorylates Rb rendering it inactive, allowing E2F to up regulate genes responsible for DNA synthesis. |
| === Genetic Instability === | === Genetic Instability === | ||
| - | Normal cells have tight regulations during the cell cycle to prevent mutations from occuring. However, when this tight regulation of the cell cycle is lost there will be an accumulation of genomic mutations during a series of cell divisions. These alterations will transform normal cells into precancerous cells. These cells would not be classified or diagnosed as cancer cells, however, these cells have a higher potential to be cancerous. The adition of more mutations that lead to increased growth trasform these cells into cancerous cells, and thus can be diagnsed as cancer. Furthermore, the cancer cells will continue to alter these cancer cells to be more malignant. Thus, genetic instability not only leads to tumorigenesis, but maintains the survivability of these cancer cells (Shen. 2011) | + | Normal cells have tight regulations during the cell cycle to prevent mutations from occuring. However, when this tight regulation of the cell cycle is lost there will be an accumulation of genomic mutations during a series of cell divisions. These alterations will transform normal cells into precancerous cells. These cells would not be classified or diagnosed as cancer cells, however, these cells have a higher potential to be cancerous. The addition of more mutations that lead to increased growth transform these cells into cancerous cells, and thus can be diagnosed as cancer. Furthermore, the cancer cells will continue to alter these cancer cells to be more malignant. Thus, genetic instability not only leads to tumorigenesis, but maintains the survivability of these cancer cells (Shen. 2011). The progression of normal cells to cancerous cells is outlined in figure 11. |
| {{ :gene_insta.png |}} | {{ :gene_insta.png |}} | ||
| - | Figure_: The accumulation of mutations due to genetic instability transforms normal cells into pre-cancerous cells, and finally into cancerous cells. | + | **Figure 11**: The accumulation of mutations due to genetic instability transforms normal cells into pre-cancerous cells, and finally into cancerous cells. |
| Line 129: | Line 128: | ||
| **Bevacizumab (Avastin®)** | **Bevacizumab (Avastin®)** | ||
| - | Bevacizumab (Avastin®) is a monoclonal antibody implemented in GBM chemotherapeutic regiments to target vascular endothelial growth factor (VEGF) and was approved by the FDA in 2009 after clinical trials had demonstrated excellent performance. The VEGF protein is needed for angiogenesis, a process that involves the synthesis of new vasculature from pre-existing vessels and occurs during wound healing and when cells are deficient in oxygen levels. The synthesis of new blood vessels among tumor cells mediated by VEGF leads to a greater blood and oxygen supply necessary for the proliferation of GBM cells (Gil-Gil et al. 2013). Avastin works to reduce vascular permeability and edema, enhancing delivery of oxygen to brain cells and reducing necrosis in the tumor core when administered in conjunction with radiation therapy (Davis 2016). According to Gil-Gil et al. 2013, GBM cells generate the proangiogenic factor called VEGF which binds with its tyrosine kinase receptor on the surface of endothelial cells, initiating a signal cascade resulting in angiogenesis. Figure 7 demonstrates that Bevacizumab is easily able to penetrate the selectively permeable blood-brain barrier with a molecular weight of 149 kDa and binds with a high affinity to VEGF, sterically inhibiting the factor from binding to its receptors on endothelial cells and effectively reducing angiogenesis, inhibiting tumor growth, and edema in the brain. | + | Bevacizumab (Avastin®) is a monoclonal antibody implemented in GBM chemotherapeutic regiments to target vascular endothelial growth factor (VEGF) and was approved by the FDA in 2009 after clinical trials had demonstrated excellent performance. The VEGF protein is needed for angiogenesis, a process that involves the synthesis of new vasculature from pre-existing vessels and occurs during wound healing and when cells are deficient in oxygen levels. The synthesis of new blood vessels among tumor cells mediated by VEGF leads to a greater blood and oxygen supply necessary for the proliferation of GBM cells (Gil-Gil et al. 2013). Avastin works to reduce vascular permeability and edema, enhancing delivery of oxygen to brain cells and reducing necrosis in the tumor core when administered in conjunction with radiation therapy (Davis 2016). According to Gil-Gil et al. 2013, GBM cells generate the proangiogenic factor called VEGF which binds with its tyrosine kinase receptor on the surface of endothelial cells, initiating a signal cascade resulting in angiogenesis. Figure 12 demonstrates that Bevacizumab is easily able to penetrate the selectively permeable blood-brain barrier with a molecular weight of 149 kDa and binds with a high affinity to VEGF, sterically inhibiting the factor from binding to its receptors on endothelial cells and effectively reducing angiogenesis, inhibiting tumor growth, and reducing edema in the brain. |
| {{ :avastin.png?500 |}} | {{ :avastin.png?500 |}} | ||
| - | **Figure 7** : This figure depicts the mechanism by which Bevacizumab works to inhibit VEGF receptors on the surface of endothelial cells | + | **Figure 12** : This figure depicts the mechanism by which Bevacizumab works to inhibit VEGF receptors on the surface of endothelial cells |
| **Radiation Therapy and Temozolomide** | **Radiation Therapy and Temozolomide** | ||
| - | Following the surgical removal of the tumour, patients undergo various forms of radiation therapy (RT), most commonly RT is externally delivered in which ionizing radiation is targeted at cancer cells left in the brain following resection, damaging DNA and resulting in apoptosis (Davis, 2016). One the most effective forms of RT is brachytherapy, particularly the use of a new device approved in 2002 called GliaSite. This involves the administration of 125I solution which is filled into a closed catheter ballon and inflated to fill the resection cavity (Chan et al., 2005). Following and often times concurrently with RT, patients are put on a 4-6 week chemotherapeutic regime, they are administered a drug called temozolomide (TMZ) (Davis, 2016). Temozolomide is a small (194 Da) lipophilic molecule that is available as an orally administered chemotherapeutic pill. Due to TMZ’s small size and lipophilic character, it readily crosses the blood-brain barrier (Agarwalla & Kirkwood, 2000). Once TMZ is in the body it is rapidly metabolized into MTIC, which is an alkylating agent that adds a methyl group to the O6 position of guanine in DNA, this results in the incorporation of a thymine residue instead of a cytosine residue across the methylated guanine (Zhang, Stevens & Bradshaw, 2012). The abnormal thymine-guanine pair leads to DNA mismatch repair activation, in which the mispaired thymine is excised but the the methylated guanine is left, eventually, cycles of this leads to breaks in the DNA and apoptosis. It is important to note that there can be resistance to TMZ and its alkylating activity, specifically via a protein known as O6-methylguanine methyltransferase (MGMT). MGMT protects cells from carcinogens and consequently, it can also protect and resist chemotherapeutic agents like TMZ. MGMT is able to transfer the O6-alkyl group on guanine, to its active site (cysteine 145), effectively repairing DNA and therefore evading apoptosis (Zhang, Stevens & Bradshaw, 2012). | + | Following the surgical removal of the tumour, patients undergo various forms of radiation therapy (RT), most commonly RT is externally delivered in which ionizing radiation is targeted at cancer cells left in the brain following resection, damaging DNA and resulting in apoptosis (Davis, 2016). One the most effective forms of RT is brachytherapy, particularly the use of a new device approved in 2002 called GliaSite. This involves the administration of 125I solution which is filled into a closed catheter ballon and inflated to fill the resection cavity (Chan et al., 2005). Following and often times concurrently with RT, patients are put on a 4-6 week chemotherapeutic regime, they are administered a drug called temozolomide (TMZ) (Davis, 2016). Temozolomide is a small (194 Da) lipophilic molecule that is available as an orally administered chemotherapeutic pill. Due to TMZ’s small size and lipophilic character, it readily crosses the blood-brain barrier (Agarwalla & Kirkwood, 2000). Once TMZ is in the body it is rapidly metabolized into MTIC, which is an alkylating agent that adds a methyl group to the O6 position of guanine in DNA, this results in the incorporation of a thymine residue instead of a cytosine residue across the methylated guanine (Zhang, Stevens & Bradshaw, 2012). The abnormal thymine-guanine pair leads to DNA mismatch repair activation, in which the mispaired thymine is excised but the the methylated guanine is left, eventually, cycles of this leads to breaks in the DNA and apoptosis. It is important to note that there can be resistance to TMZ and its alkylating activity, specifically via a protein known as O6-methylguanine methyltransferase (MGMT). MGMT protects cells from carcinogens and consequently, it can also protect and resist chemotherapeutic agents like TMZ. MGMT is able to transfer the O6-alkyl group on guanine (Figure 13), to its active site (cysteine 145), effectively repairing DNA and therefore evading apoptosis (Zhang, Stevens & Bradshaw, 2012). |
| {{ :tmzz.png |}} | {{ :tmzz.png |}} | ||
| - | **Figure 8**: Repair of O6-methylguanine by MGMT | + | **Figure 13**: Repair of O6-methylguanine by MGMT |
| - | + | ||
| - | **Immune Checkpoints** | + | |
| - | + | ||
| - | Novel progression of sequencing methods have led to the identification of specific molecular signatures of GBM. There are several biomarkers which are used for identification. The types include, diagnostic, prognostic, and predictive. Predictive biomarkers help in the treatment allowing the use of patient-specific biology. This uproots anti-GBM therapies to be used as molecular inhibitors that will target the growth factor receptors. Part of the GBM's growth is correlated to its ability to escape the individual's immune system surveillance. GBM dampens the immune response via expression of immunosuppressive cytokines such as prostaglandin E2 and transforming growth factor beta. It also increases the activation of T-cells. It affects two major checkpoint proteins, cytotoxic T-lyphocyte antigen 4 (CTLA-4) and the programmed cell death protein 1 (PD-1). CTLA-4 will increase T-cell activity while also competing with CD28 for binding with B7 ligands. PD-1 regulates immunity at several phases of the immune response. High expression of PD-L1 mRNA and CTLA-4 in GBM suggests a correlation between the immune checkpoint proteins and the severity of | + | |
| ===Upcoming Treatment=== | ===Upcoming Treatment=== | ||
| - | The prospective treatment will include an oncolytic vaccine using a genetically engineered herpes simplex virus (HSV) (Wollman, 2013). The oncolytic virus must be altered to be invasive but not pathogenic and Tumor Associated Antigens (TAAs) must be incorporated in the genome in order to increase immune response. There are several antigens that are expressed solely on cancer cell membranes such as CD133+ and others that have already been associated with decreased tumor size such as EphA2, IL13Ralpha2 (Hatano 2005, Okano 2002, Signh 2003). | + | The prospective treatment will include an oncolytic vaccine using a genetically engineered herpes simplex virus (HSV) (Wollman, 2013). The oncolytic virus must be altered to be invasive but not pathogenic and Tumor Associated Antigens (TAAs) must be incorporated in the genome in order to increase immune response. There are several antigens that are expressed solely on cancer cell membranes such as CD133+ and others that have already been associated with decreased tumor size such as EphA2, IL13Ralpha2 (Hatano 2005, Okano 2002, Singh 2003). |
| - | To treat the efficacy of the treatment in vivo, a syngeneic mouse model will be used where mouse GBM cells will be harvested and transplanted intracranially. This method is advantageous compared to xenograft because the mouse can have a fully functioning immune system and lowers the chance of transplant rejection (Jiang, 2017). Tumor size and growth will be monitored through MRI technology to get a baseline. The mice will then be separated into control and experimental groups, the former will receive no treatment and the latter will receive the HSV oncolytic virus therapy (Ni, 2016). Tumor recession will be monitored via YKL-40, an angiogenesis factor, to determine vascular necrosis (Tanwar, 2002). CD8+ activation will also be measured by recording serum CD8 (sCD8) levels to monitor immune response (Nishanian 1991). And lastly overall mass will be visualized through MRI technology (Ni, 2016). | + | To treat the efficacy of the treatment in vivo, a syngeneic mouse model will be used where mouse GBM cells will be harvested and transplanted intracranially. This method is advantageous compared to xenograft because the mouse can have a fully functioning immune system and lowers the chance of transplant rejection (Jiang, 2017). Tumor size and growth will be monitored through MRI technology to get a baseline. Referring to Figure 14, the mice will then be separated into control and experimental groups, the former will receive no treatment and the latter will receive the HSV oncolytic virus therapy (Ni, 2016). Tumor recession will be monitored via YKL-40, an angiogenesis factor, to determine vascular necrosis (Tanwar, 2002). CD8+ activation will also be measured by recording serum CD8 (sCD8) levels to monitor immune response (Nishanian 1991). And lastly overall mass will be visualized through MRI technology (Ni, 2016). |
| {{:oncolytic_vaccine.png|}} | {{:oncolytic_vaccine.png|}} | ||
| Line 154: | Line 149: | ||
| - | Figure_: In the control group, mice will only be injected with mouse GBM cells. The treatment group will be injected with mouse GBM cells and the oncolytic vaccine. Tumour size and immune activation will be measured to tract efficacy of the treatment. | + | **Figure 14**: In the control group, mice will only be injected with mouse GBM cells. The treatment group will be injected with mouse GBM cells and the oncolytic vaccine. Tumour size and immune activation will be measured to tract efficacy of the treatment. |
| + | |||
| + | ====== Conclusion ====== | ||
| + | In summary, Glioblastoma is one of the most aggressive and lethal cancers prevalent in the central nervous system. With a very high mitotic and recurrence rate following conventional therapeutic options, Glioblastoma delivers a poor prognosis following patient diagnosis. In spite of the poor outlook of survivability, if dealt with in its benign grade 1 stages, most treatments can be considered curative. However, for grade 4 glioblastomas, current therapeutics in the works are attempting to improve chances of patient survival by looking at novel ways to halt uncontrollable cellular proliferation and manage the preservation of healthy brain tissue, in an attempt to reduce the morbidity rate of patients diagnosed with GBM. | ||
| ====== References ====== | ====== References ====== | ||
| Agarwala, S. A., & Kirkwood, J. M. (2000). Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic Melanoma. The Oncologist, 5, 144-151. doi: 10.1634/theoncologist.5-2-144 | Agarwala, S. A., & Kirkwood, J. M. (2000). Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic Melanoma. The Oncologist, 5, 144-151. doi: 10.1634/theoncologist.5-2-144 | ||
| + | |||
| + | Ahmed, A. U., Auffinger, B., & Lesniak, M. S. (2013). Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies. Expert review of neurotherapeutics, 13(5), 545-555. http://dx.doi.org/10.1586/ern.13.42 | ||
| + | |||
| + | Alifieris, C., & Trafalis, D. T. (2015). Glioblastoma multiforme: Pathogenesis and treatment. Pharmacology & therapeutics, 152, 63-82. https://doi.org/10.1016/j.pharmthera.2015.05.005 | ||
| Avastin: Important Safety Information. (n.d.). Retrieved September 28, 2017, from https://www.avastin-hcp.com/about-avastin/proposed-moa.html | Avastin: Important Safety Information. (n.d.). Retrieved September 28, 2017, from https://www.avastin-hcp.com/about-avastin/proposed-moa.html | ||
| Line 168: | Line 170: | ||
| Gil-Gil, M. J., Mesia, C., Rey, M., & Bruna, J. (2013). Bevacizumab for the Treatment of Glioblastoma. Clinical Medicine Insights. Oncology, 7, 123–135. http://doi.org/10.4137/CMO.S8503 | Gil-Gil, M. J., Mesia, C., Rey, M., & Bruna, J. (2013). Bevacizumab for the Treatment of Glioblastoma. Clinical Medicine Insights. Oncology, 7, 123–135. http://doi.org/10.4137/CMO.S8503 | ||
| + | |||
| + | Hatano, M., Eguchi, J., Tatsumi, T., Kuwashima, N., Dusak, J. E., Kinch, M. S., ... & Okada, H. (2005). EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia, 7(8), 717-722. https://doi.org/10.1593/neo.05277 | ||
| Henson, J. W. (1999). Glioblastoma multiform and anaplastic gliomas: A patient guide. MGH Brain Tumor Center. Retrieved from https://brain.mgh.harvard.edu/patientguide.htm | Henson, J. W. (1999). Glioblastoma multiform and anaplastic gliomas: A patient guide. MGH Brain Tumor Center. Retrieved from https://brain.mgh.harvard.edu/patientguide.htm | ||
| + | |||
| + | Herbst, R. S. (2004). Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology* Biology* Physics, 59(2), S21-S26.https://doi.org/10.1016/j.ijrobp.2003.11.041 | ||
| + | |||
| + | Jiang, H., Rivera-Molina, Y., Clise-Dwyer, K., Bover, L., Vence, L., Yuan, Y., ... & Fueyo, J. (2017). Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Research, canres-0468. doi: 10.1158/0008-5472.CAN-17-0468 | ||
| Louis, D. N., Perry, A., Reifenberger, G., Von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., Ellison, D. W. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 131(6), 803-820. https://doi.org/10.1007/s00401-016-1545-1 | Louis, D. N., Perry, A., Reifenberger, G., Von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., Ellison, D. W. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 131(6), 803-820. https://doi.org/10.1007/s00401-016-1545-1 | ||
| Line 176: | Line 184: | ||
| Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J.-I. (2011). Aberrant Signaling Pathways in Glioma. Cancers, 3(3), 3242–3278. http://doi.org/10.3390/cancers3033242 | Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J.-I. (2011). Aberrant Signaling Pathways in Glioma. Cancers, 3(3), 3242–3278. http://doi.org/10.3390/cancers3033242 | ||
| + | |||
| + | Nevins, J. R. (2001). The Rb/E2F pathway and cancer. Human molecular genetics, 10(7), 699-703. https://doi.org/10.1093/hmg/10.7.699 | ||
| + | |||
| + | Ni, J., Ramkissoon, S. H., Xie, S., Goel, S., Stover, D. G., Guo, H., ... & Hayashi, M. (2016). Combination inhibition of PI3K and mTORC1 yields durable remissions in orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature medicine, 22(7), 723. | ||
| + | Chicago. https://dx.doi.org/10.1038%2Fnm.4120 | ||
| + | |||
| + | Nishanian, P., Hofmann, B., Wang, Y., Jackson, A. L., Detels, R., & Fahey, J. L. (1991). Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-1 disease. Aids, 5(7), 805-812. | ||
| + | |||
| + | Okano, F., Storkus, W. J., Chambers, W. H., Pollack, I. F., & Okada, H. (2002). Identification of a novel HLA-A* 0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor α2 chain. Clinical Cancer Research, 8(9), 2851-2855. DOI: published Sept. 2002. | ||
| + | |||
| + | Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., & Dirks, P. B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer research, 63(18), 5821-5828. Doi: published Sept 2003. | ||
| Sizoo, E. M., Braam, L., Postma, T. J., Pasman, H. R. W., Heimans, J. J., Klein, M., … Taphoorn, M. J. B. (2010). Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro-Oncology, 12(11), 1162–1166. http://doi.org/10.1093/neuonc/nop045 | Sizoo, E. M., Braam, L., Postma, T. J., Pasman, H. R. W., Heimans, J. J., Klein, M., … Taphoorn, M. J. B. (2010). Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro-Oncology, 12(11), 1162–1166. http://doi.org/10.1093/neuonc/nop045 | ||
| + | |||
| + | Tanwar, M. K., Gilbert, M. R., & Holland, E. C. (2002). Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer research, 62(15), 4364-4368. doi: published Aug 2002 | ||
| Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014). Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 23(10), 1985–1996. http://doi.org/10.1158/1055-9965.EPI-14-0275 | Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014). Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 23(10), 1985–1996. http://doi.org/10.1158/1055-9965.EPI-14-0275 | ||
| - | Young, R. M., Jamshidi, A., Davis, G., & Sherman, J. H. (2015). Current trends in the surgical management and treatment of adult glioblastoma. Annals of Translational Medicine, 3(9), 121. http://doi.org/10.3978/j.issn.2305-5839.2015.05.10 | + | Walid, M. S. (2008). Prognostic Factors for Long-Term Survival after Glioblastoma. The Permanente Journal, 12(4), 45–48. |
| Williamson, J. (n.d.). What Is a Fat Burner? Retrieved from http://www.healthguidance.org/entry/14407/1/What-Is-a-Fat-Burner.html | Williamson, J. (n.d.). What Is a Fat Burner? Retrieved from http://www.healthguidance.org/entry/14407/1/What-Is-a-Fat-Burner.html | ||
| + | |||
| + | Wollmann, G., Ozduman, K., & van den Pol, A. N. (2012). Oncolytic virus therapy of glioblastoma multiforme–concepts and candidates. Cancer journal (Sudbury, Mass.), 18(1), 69. https://dx.doi.org/10.1097%2FPPO.0b013e31824671c9 | ||
| + | |||
| + | Young, R. M., Jamshidi, A., Davis, G., & Sherman, J. H. (2015). Current trends in the surgical management and treatment of adult glioblastoma. Annals of Translational Medicine, 3(9), 121. http://doi.org/10.3978/j.issn.2305-5839.2015.05.10 | ||
| Zhang, J., Stevens, F. G., & Bradshaw, T. D. (2012). Temozolomide: Mechanisms of Action, Repair and Resistance. Curr Mol Pharmacol., 5, 102-114. | Zhang, J., Stevens, F. G., & Bradshaw, T. D. (2012). Temozolomide: Mechanisms of Action, Repair and Resistance. Curr Mol Pharmacol., 5, 102-114. | ||
